---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-001074"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2024-01-04T23:59:59+00:00"
generated_at: "2026-06-07T03:53:58.923224+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "medium"
source: SEC EDGAR
---

# Cocrystal reports favorable preliminary safety for CDI-988 (Phase 1) and CC-42344 (Phase 2a) antivirals

## Summary
- CDI-988 (pan-norovirus/coronavirus 3CL protease inhibitor) Phase 1 in Australia shows favorable safety in single-ascending dose cohorts.
- CC-42344 (influenza A PB2 inhibitor) Phase 2a in UK shows favorable tolerability in first cohort of challenge study.
- Cocrystal expects to report topline results for both Phase 1 and Phase 2a studies in 2024.

## SEC filing metadata
- accession: 0001493152-24-001074
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2024-01-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000149315224001074/0001493152-24-001074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000149315224001074/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-001074
- JSON: https://secwatch.observer/filing/0001493152-24-001074.json
- Plain text: https://secwatch.observer/filing/0001493152-24-001074.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.